Search Clinical Trials in the European Union

Duration
Visits
Safety phase (I)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
361-380 of 936 trials

Advanced Solid Tumors: ANV600 and Pembrolizumab Study

We are testing a new treatment, ANV600, alone and with pembrolizumab for people with advanced solid tumors. The goal is to evaluate safety and how well it may help fight cancer.

Advanced Solid Tumors>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Peripheral T Cell Lymphoma: LIS1 Antibody Study

We are testing a new antibody treatment for patients with relapsed or refractory peripheral T cell lymphoma. The study aims to evaluate its safety and effectiveness in fighting this type of cancer.

Peripheral T-cell Lymphoma>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesCost ReimbursementHematologyOncology

Cholesterol Management: Rosuvastatin 10 mg

We are examining whether a new formulation of Rosuvastatin 10 mg works the same as the current version for managing cholesterol levels. This study is for individuals who need cholesterol-lowering treatment.

Healthy Volunteers6-12 monthsSafety phase (I)CardiologyInternal Medicine

ADP-TILIL7: New Treatment Study

We are exploring a new treatment for patients with specific health conditions. Our goal is to understand its effects and potential benefits compared to existing therapies.

Advanced Melanoma>2 yearsSafety phase (I)Oncology

Radiprodil for Children with GRIN-related Disorder

We are studying a new medication to see if it is safe and helps reduce seizures and improve behavior in children with GRIN-related disorder. This trial aims to find the right dose and understand its effects over time.

GRIN-related Disorder>2 yearsSafety phase (I)No PlaceboInvestigational MedicinesNeurologyPediatrics

High-Risk Neuroblastoma: Dinutuximab Beta with Chemotherapy

We are studying the safety and effectiveness of combining dinutuximab beta with two chemotherapy regimens for children with newly diagnosed high-risk neuroblastoma. This research aims to improve treatment options and outcomes for these young patients.

Neuroblastoma>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesHematologyOncologyPediatrics

Alzheimer's Disease: RO7126209 IV Treatment Study

We are investigating a new intravenous medication for individuals with mild to moderate Alzheimer's disease. The study aims to assess its safety and how it affects the brain over multiple doses.

Alzheimer's Disease>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessInvestigational MedicinesPartially RemoteNeurologyPsychiatry

Solid Tumors: PYX-201 Treatment Study

We are testing a new drug, PYX-201, for patients with solid tumors. This study aims to understand its safety and how it may work in treating cancer.

Advanced Solid TumorsSafety phase (I)Oncology

Ponatinib for Pediatric Leukemias and Solid Tumors

We are studying the safety and effectiveness of ponatinib in children with recurrent or hard-to-treat leukemias and solid tumors. This trial aims to help those who have not responded to other therapies.

Acute Myeloid LeukaemiaChronic Myeloid Leukaemia1-2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteHematologyOncology

CART Cell Therapy for Acute Lymphoblastic Leukemia in Young Patients

We are studying the safety and feasibility of new CART cell therapies for children and young adults with relapsed or refractory acute lymphoblastic leukemia. This trial aims to find better treatment options for those who have not responded to current therapies.

Acute Lymphoblastic Leukemia (ALL)>2 yearsSafety phase (I)No PlaceboInvestigational MedicinesHematologyOncology

ARO-DUX4 for Facioscapulohumeral Muscular Dystrophy Type 1

We are studying a new treatment for adults with Facioscapulohumeral Muscular Dystrophy Type 1 to see how safe it is and how it works in the body. This trial will help us understand its effects with different doses.

Facioscapulohumeral Muscular Dystrophy1-2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementInternal MedicineNeurology

Advanced PRAME Positive Cancers: IMC-P115C Treatment

We are testing a new treatment called IMC-P115C for patients with advanced cancers that are PRAME positive. This study aims to evaluate the safety and appropriate dosage of this new therapy.

Clear Cell Endometrial CarcinomaNon-Small Cell Lung CancerSmall Cell Lung Cancer>2 yearsSafety phase (I)Oncology

Advanced Solid Tumors: BI-1206 with Pembrolizumab

We are studying a new treatment combining BI-1206 and pembrolizumab for patients with advanced solid tumors. This trial aims to find a safe dose and understand how well this combination works for those with specific types of cancer.

Malignant Solid Tumor>2 yearsSafety phase (I)Efficacy phase (II)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementInternal MedicineOncology

Advanced Cancers: BI-1808 Monoclonal Antibody

We are studying a new treatment called BI-1808 for people with advanced cancers, both alone and with pembrolizumab. The goal is to assess its safety and how well it is tolerated by patients.

Malignant Solid Tumor>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesOncology

DOK7 Congenital Myasthenic Syndrome: ARGX-119 Study

We are investigating the safety and tolerability of a new treatment, ARGX-119, for adults with DOK7 Congenital Myasthenic Syndrome. This study aims to understand how well the treatment is tolerated in this specific group.

Congenital Myasthenic Syndrome1-2 yearsSafety phase (I)Efficacy phase (II)Internal MedicineNeurology

Alzheimer’s Disease: Trontinemab Study

We are assessing how a new monoclonal antibody, Trontinemab, behaves in the brains of healthy individuals and those with Alzheimer’s disease. This study aims to understand its distribution and retention in the brain.

Alzheimer's Disease3-6 monthsSafety phase (I)Neurology

ZP9830: New Medication Study

We are testing different doses of ZP9830 in healthy volunteers to see how it affects the body. This research helps us find safe dosage levels for future treatments.

Autoimmune Diseases1-2 yearsSafety phase (I)Internal Medicine

Melanoma Treatment: Comparing Pembrolizumab Formulations

We are studying whether a new formulation of Pembrolizumab is similar to existing treatments for patients with completely removed stage IIB, IIC, and III melanoma. This research aims to ensure effective adjuvant therapy options for these patients.

Stage IIB, IIC, and III Melanoma>2 yearsSafety phase (I)DermatologyOncology

Mucopolysaccharidosis IIIA: Gene Therapy Study

We are testing a new gene therapy called UX111 for individuals with Mucopolysaccharidosis IIIA. The goal is to see if it is safe and effective in treating this condition.

Mucopolysaccharidosis III>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHematologyInternal MedicineNeurologyPediatrics

Safety Study of AIC263029 Medication

We are investigating whether AIC263029 is safe when given once or multiple times. This study will also look at how the medication moves through the body.

BK Virus Nephropathy1-2 yearsSafety phase (I)Infectious DiseasesNephrology